News

FWF’s ESPRIT Program supports Research on β-Catenin in Wilms Tumor  The Austrian Science Fund’s ESPRIT program has awarded funding to Maud Plaschka’s project focused on exploring β-catenin’s role in Wilms tumor, recognizing the need for innovative research in pediatric oncology. This initiative aims to determine the therapeutic potential of β-catenin inhibitors, addressing a significant gap […]

MSCA Postdoctoral Fellowship enables the building of fusion-driven Sarcoma Models Sarcomas, aggressive tumors that primarily affect children and adolescents, are the focus of a new project at St. Anna CCRI.  Despite advanced medicine, survival rates of patients with Sarcomas are low and treatment methods are outdated. Strengthened by a prestigious Marie Curie Postdoctoral Fellowship, Ornella Urzì is

When Acute Lymphoblastic Leukemia (ALL) Transforms (Vienna, 05.04.2024) Acute lymphoblastic leukemia (ALL) is highly treatable. However, for new treatment methods in personalized medicine, subtypes of this leukemia must be studied more thoroughly. A team of researchers from St. Anna Children’s Cancer Research Institute and the University of Padua has now made another step forward in

The two faces of neutrophils in tumor biology (Vienna, 26.03.2024) Neutrophils are the most common white blood cells and an important component of the immune system. They help in the defense against pathogens and in the healing of injuries. They are also suspected to play a role in tumor development. A team from St. Anna

Researchers investigate the control center for maintaining immune cell fitness  (Vienna, 14.03.2024) The endoplasmic reticulum in human immune cells is the topic of a current research project at the St. Anna Children’s Cancer Research Institute (CCRI). This highly complex network of membrane structures is where the cells proteins are produced and the quality control processes that

United Fight Against Osteosarcoma: Innovative T-Cell Therapy Research (Vienna, March 12, 2024) The St. Anna Children’s Cancer Research Institute is at the forefront of a groundbreaking research initiative targeting osteosarcoma, the most prevalent aggressive bone cancer in children and young adults. The project, DART2OS, spearheaded by the Institute of Molecular Pathology (IMP) and supported by the

International Women’s Day: Spotlight on the Power of Women  (Vienna, 8.3.2024) In celebration of International Women’s Day, we proudly highlight the incredible women of St. Anna Children’s Cancer Research Institute, where an inspiring 67% of our dedicated team members are women. Among them stand Principal Investigators Eleni Tomazou and Sabine Taschner-Mandl, whose contributions shape the landscape

Why Rare Disease Research Matters – Today is Rare Disease Day 2024 Today, on Rare Disease Day, we’re proud to release a special video featuring researchers from around the globe! Join us as they share why research into rare diseases is vital and how it can make a profound impact on countless lives. Together with the

St. Anna CCRI wants to develop new drug against Ewing sarcoma with international partners A three-year project aims to improve the long-term survival rate of patients with Ewing sarcoma. (Vienna, 22.02.2024) Ewing sarcoma is a very aggressive, rapidly metastasizing bone cancer. In Austria, five to eight children and adolescents are affected every year. The long-term

Wolf vs. Sheep – Game Release on International Childhood Cancer Day 2024 (Vienna, 15.2.2023) Today, we stand united under the golden ribbon – it’s International Childhood Cancer Day. A day to reflect on the fact that children aren’t simply „little“ adults, and their cancer journey demands dedicated research for tailored treatments. Bioinformatics plays a crucial role

CML: A new combination therapy against resistant leukemia (Vienna, 6.2.2024) In a new publication in the American Journal of Hematology, scientists at St. Anna Children’s Cancer Research Institute show a treatment option for chronic myeloid leukemia with highly resistant multiple mutations that have eluded previous therapies. Chronic myeloid leukemia (CML) is a slowly progressing cancer. It

World Cancer Day 2024: Collaboration is Key (Vienna, 4.2.2024) Todays World Cancer Day reminds us of the urgent need for a collective effort in understanding Childhood Cancer and enhancing treatments for children bravely facing this formidable disease. In the realm of Childhood Cancer, international collaboration is paramount. Recognizing that individual nations working in isolation would not be

Exploring Horizons: SIOPEN Translational Research Meeting in Vienna (Vienna, 31.1.2024) Over the past three days, scientists from leading institutes such as St. Anna CCRI, Charite, Curie, Prinses Maxima Center, University of Leeds and the Vall d’Hebron University Hospital engaged in dynamic discussions on pivotal topics, spanning the realms of Liquid Biopsies, Tumor Biology, and New

Neuroblastoma: Liquid biopsies to detect relapse of childhood cancer early (Vienna, 29.1.2024) Neuroblastoma mainly affects toddlers and young children – in the EU region there are 1500 new cases per year. Neuroblastoma is a malignant tumor of the peripheral nervous system and around 50% of patients are high-risk cases. Recurrences occur frequently, and conventional therapies are

CCRI – CeMM Collaboration Agreement (Vienna, 22.01.2024) CCRI Directors Kaan Boztug and Jörg Bürger, and CeMM Directors Giulio Superti-Furga and Anita Ender have signed a partnership agreement which further strengthens scientific collaborations and training aspects.  CeMM’s research is strongly oriented towards medical needs and integrates research on fundamental biological processes with clinical expertise to gain